The three EU member states join Germany and Italy in their recommendations, citing insufficient clinical trial data.
Primary analysis of phase III trials also showed that the vaccine efficacy is stronger when the period between the two doses is lengthened to 12 weeks.
The European Medicines Agency says it is not restricting use of the vaccine for people aged over 55 in order to 'give options', but some member states are set to withhold it
"The problem for the European Commission is going to be once the rollout happens, it's not going to get the credit. The member states ... are going to take the credit," said Finland's ex-PM Alexander Stubb
The row over the supply of COVID-19 vaccines highlights the tension as Europe struggles to roll out inoculation programmes.
The chief executive of the pharmaceutical giant assured that the vaccine developed with Oxford University should be effective against the new coronavirus strain sweeping the UK.